Published in Tex Rep Biol Med on January 01, 1977
Modified polyriboinosinic-polyribocytidylic acid complex: sustained interferonemia and its physiological associates in humans. Infect Immun (1979) 1.05
Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors. J Pediatr Hematol Oncol (2014) 0.80
Replication of semliki forest virus: three forms of viral RNA produced during infection. Proc Natl Acad Sci U S A (1966) 3.23
A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J Infect Dis (1975) 2.14
Inhibition of tumor growth by polyinosinic-polycytidylic acid. Proc Natl Acad Sci U S A (1969) 2.00
Molecular basis of the action of interferon. J Mol Biol (1968) 1.70
Interferon preparations as modifiers of immune responses. Proc Soc Exp Biol Med (1972) 1.44
The recognition of viral RNA by mammalian ribosomes. An effect of interferon. Biochim Biophys Acta (1968) 1.44
Ribosomes: effect of interferon on their interaction with rapidly labeled cellular and viral RNA's. Science (1967) 1.44
A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. J Natl Cancer Inst (1976) 1.42
Inhibition of biologic activity of poly I: poly C by human plasma. Proc Soc Exp Biol Med (1970) 1.42
Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery (1996) 1.39
Some factors affecting the interferon-induced antiviral state. Proc Soc Exp Biol Med (1967) 1.33
Successful prophylaxis against rabies in mice and Rhesus monkeys: the interferon system and vaccine. J Infect Dis (1977) 1.33
Effect of interferon on early interferon production. Science (1966) 1.30
Interferon action on parental Semliki forest virus ribonucleic acid. J Virol (1967) 1.28
An interdisciplinary method of classifying and monitoring medication errors. Am J Hosp Pharm (1985) 1.19
Effect of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid complex on yellow fever in rhesus monkeys (Macaca mulatta). J Infect Dis (1977) 1.19
The effect of polyinosinic-polycytidylic acid upon graft-vs-host activity in BALB/c mice. J Immunol (1970) 1.18
Interferon and uninfected cells. Proc Soc Exp Biol Med (1966) 1.15
Modification of chronic hepatitis-B virus infection in chimpanzees by administration of an interferon inducer. Lancet (1976) 1.10
Interferon: lack of detectable uptake by cells. Science (1966) 1.09
Modified polyriboinosinic-polyribocytidylic acid, an immunological adjuvant. Infect Immun (1976) 1.09
Interferon and interferon inducers in the treatment of malignancies. Arch Intern Med (1970) 1.08
Protective and toxic effects of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid on Venezuelan equine encephalomyelitis virus in rhesus monkeys. J Infect Dis (1979) 1.07
Modified polyriboinosinic-polyribocytidylic acid complex: sustained interferonemia and its physiological associates in humans. Infect Immun (1979) 1.05
Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice. Antimicrob Agents Chemother (1995) 1.04
Swine influenza virus vaccine: potentiation of antibody responses in rhesus monkeys. Science (1977) 1.03
Lack of correlation between interferon induction and antitumour effect of poly I-poly C. Nat New Biol (1971) 1.02
Interferon induction in cynomolgus and rhesus monkey after repeated doses of a modified polyriboinosinic-polyribocytidylic acid complex. Antimicrob Agents Chemother (1977) 1.01
Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer. Cancer Res (1979) 1.01
Phase I-II trials of poly IC stabilized with poly-L-lysine. Cancer Treat Rep (1978) 1.00
A preliminary trial of poly(I,C)-LC in multiple sclerosis. J Biol Response Mod (1985) 0.99
Postinfectious encephalopathy after treatment of herpes simplex encephalitis with acyclovir. Pediatr Infect Dis (1984) 0.99
The effect of interferon, interferon inducers or interferon induced virus resistance on subsequent interferon production. J Gen Virol (1972) 0.97
Induction of interferon in lymphoblastoid cell lines. Proc Soc Exp Biol Med (1970) 0.96
Interferon. Annu Rev Microbiol (1966) 0.95
Mechanisms of DEAE-dextran enhancement of polynucleotide induction of interferon. Proc Soc Exp Biol Med (1971) 0.94
Prophylactic control of simian hemorrhagic fever in monkeys by an interferon inducer, polyriboinosinic-polyribocytidylic acid-poly-L-lysine. J Infect Dis (1976) 0.91
Studies on poly I:C toxicity in experimental animals. Toxicol Appl Pharmacol (1972) 0.90
The effect of polyinosinic:polycytidylic acid on tumor metabolism. Proc Soc Exp Biol Med (1970) 0.89
Effect of interferon on togavirus and arenavirus infections of animals. Tex Rep Biol Med (1977) 0.89
Polyinosinic-polycytidylic acid inhibits chemically induced tumorigenesis in mouse skin. Science (1970) 0.88
Dactinomycin: relative resistance of green monkey kidney cell cultures to its action. Proc Soc Exp Biol Med (1967) 0.88
Treatment of intracranial alphavirus infections in mice by a combination of specific antibodies and an interferon inducer. Am J Trop Med Hyg (1995) 0.87
Topical treatment of vaccinia virus infection with an interferon inducer in rabbits. J Infect Dis (1978) 0.86
Effect of interferon on RNA synthesis in Sindbis virus infected cells. Proc Soc Exp Biol Med (1966) 0.86
Epstein-Barr virus and Herpesvirus saimiri: sensitivity to interferons and interferon inducers. J Natl Cancer Inst (1981) 0.86
Immunoprophylactic strategies against respiratory influenza virus infection. Vaccine (2001) 0.85
Protein synthesis by amoebal ribosomes. Nature (1967) 0.85
Effect of interferon treatment on cellular messenger RNA. Proc Natl Acad Sci U S A (1973) 0.85
Induction of interferon by preparations of synthetic single-stranded RNA. Proc Natl Acad Sci U S A (1969) 0.84
Antitumor effects of interferon and poly ICLC, and their possible utility as anti-neoplastic agents in man. Tex Rep Biol Med (1983) 0.83
An effective rabies treatment in exposed monkeys: a single dose of interferon inducer and vaccine. Bull World Health Organ (1979) 0.83
Historical overview of the use of polynucleotides in cancer. J Biol Response Mod (1985) 0.83
Chlorite-oxidized amylose as an adjuvant for interferon production. Infect Immun (1973) 0.82
Induction of interferon in vivo and in vitro by polynucleotides and derivatives, and preparation of derivatives. Methods Enzymol (1981) 0.82
Interferon induction in primates by stabilized polyriboinosinic acid-polyribocytidylic acid: effect of component size. Infect Immun (1981) 0.82
Postinfection therapy of arbovirus infections in mice. Antimicrob Agents Chemother (1989) 0.82
Modified polyriboinosinic-polyribocytidylic acid complex: induction of serum interferon, fever, and hypotension in rabbits. Antimicrob Agents Chemother (1980) 0.82
Immunochemotherapy for Leishmania donovani infection in golden hamsters: combinatorial action of poly ICLC plus L-arginine and sodium stibogluconate (Stibanate). J Interferon Cytokine Res (1999) 0.82
Immune modulating effects of poly ICLC. Ann N Y Acad Sci (1980) 0.81
Evaluation of polyinosinic-polycytidylic and poly-L-lysine in metastatic breast cancer. Cancer Treat Rep (1986) 0.81
Poly ICLC inhibits Plasmodium cynomolgi B malaria infection in rhesus monkeys. J Interferon Cytokine Res (1996) 0.80
Killing of Leishmania donovani amastigotes by poly ICLC in hamsters. J Interferon Cytokine Res (1996) 0.80
Poly ICLC enhances the antimalarial activity of chloroquine against multidrug-resistant Plasmodium yoelii nigeriensis in mice. J Interferon Cytokine Res (1997) 0.80
Chlamydia trachomatis infections in infants. Mt Sinai J Med (1986) 0.80
Adjuvant effects of low doses of a nuclease-resistant derivative of polyinosinic acid . polycytidylic acid on antibody responses of monkeys to inactivated Venezuelan equine encephalomyelitis virus vaccine. Infect Immun (1979) 0.80
Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice. Antimicrob Agents Chemother (1987) 0.79
Further studies on rabies postexposure prophylaxis in mice: a comparison of vaccine with interferon and vaccine. J Gen Virol (1979) 0.79
Radiation damage and the interferon system. Tex Rep Biol Med (1977) 0.79
Response of mouse tumor to interferon inducer and radiation. Int J Radiat Oncol Biol Phys (1985) 0.79
A comparison of interferon responses to poly ICLC in males and females. J Interferon Res (1985) 0.79
Cortisol induction by poly ICLC: implications for clinical trials of interferon. Ann Neurol (1988) 0.78
Post-exposure prophylaxis of murine rabies with polyinosinic-polycytidylic acid and chlorite-oxidized amylose. Antimicrob Agents Chemother (1974) 0.78
Evaluation of a nuclease-resistant derivative of poly(I) . poly(C) [poly(ICLC)] as a radioprotective agent. Radiat Res (1979) 0.78
Lack of uptake of intact polyriboinosinic-polyribocytidylic acid by cells. Proc Soc Exp Biol Med (1973) 0.78
Preliminary trial of poly ICLC in chronic progressive multiple sclerosis. Neurology (1986) 0.78
Poly(I,C)-LC as an interferon inducer in refractory multiple myeloma. J Biol Response Mod (1985) 0.78
Immune response modifying activity in mice of polyinosinic: polycytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly-ICLC]. Int J Immunopharmacol (1981) 0.77
Protectivity of herpes simplex virus antigens: studies in mice on the adjuvant effect of PICLC and on the dependence of protection on T cell competence. Med Microbiol Immunol (1981) 0.77
Topical polyriboinosinic-polyribocytidylic acid complex in the treatment of recurrent genital herpes. Antimicrob Agents Chemother (1982) 0.77
Changes in leukocyte recirculation, NK cell activity, and HLA-DR expression in peripheral blood mononuclear cells of MS patients treated with Poly ICLC. Int J Immunopharmacol (1991) 0.77
The kinetics of interferon induction by poly ICLC in humans. J Interferon Res (1988) 0.77
Interferon assay of high sensitivity. Proc Soc Exp Biol Med (1976) 0.77
Effect of interferon on cellular RNA synthesis and structure. Tex Rep Biol Med (1977) 0.76
Ranking of prophylactic efficacy of poly(ICLC) against Rift Valley fever virus infection in mice by incremental relative risk of death. Antimicrob Agents Chemother (1987) 0.76
Poly ICLC in the treatment of postinfectious demyelinating encephalomyelitis. Arch Neurol (1981) 0.76
Gamma-interferon induction in patients with chronic progressive MS. Neurology (1991) 0.76
Studies on the mechanism of interferon action: characterization of polysome-associated cellular RNAs modified by interferon. Virology (1977) 0.76
A comparison of interferon responses to poly ICLC in males and females. J Interferon Res (1992) 0.75
Modified polyriboinosinic-polyribocytidylic acid complex: modulation of toxicity for rabbits by alterations in components. Antimicrob Agents Chemother (1980) 0.75
Interferon induction by radioprotective mercaptoalkylamines and derived thiophosphates. Infect Immun (1977) 0.75
Pelger-Huët anomaly. N Y State J Med (1981) 0.75
Cardiac catheterization in children. Am Fam Physician (1981) 0.75
Amphetamines in hyperkinetic children. JAMA (1971) 0.75
Polyinosinic-polycytidylic acid treatment of neuropathy. Lancet (1978) 0.75
Paroxysmal supraventricular tachycardia in the infant. Am Fam Physician (1980) 0.75
Haemophilus influenzae type b pericarditis. Hosp Pract (1979) 0.75
Learning disabilities. JAMA (1980) 0.75
Hypertension and urologic surgery in children. Urology (1978) 0.75
Specific restoration of delayed hypersensitivity by lymphoid tissue extracts. J Immunol (1977) 0.75